<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Bill Welch, CEO

Prior to Trovagene, Mr. Welch was President and CEO at Sequenom Inc. where he introduced the first non-invasive prenatal test (NIPT) utilizing a maternal blood sample to identify fetal chromosomal abnormalities and helped establish a $3.0 global NIPT market. Prior to Sequenom, Mr. Welch was Senior Vice President, Chief Commercial Officer at Monogram Biosciences, a leader in HIV and oncology diagnostic testing services. Previously, Mr. Welch worked at La Jolla Pharmaceutical, an immunology based biotechnology company, as Vice President Sales and Marketing, and at Dade Behring MicroScan as Vice President of Global Marketing. Mr. Welch entered the healthcare industry with Abbott Laboratories where he held progressive management positions in therapeutics and medical devices.

Mr. Welch interests include the consumerization of healthcare, particularly in genomics, personalized medicine and life sciences. He has led numerous commercial and development programs through the FDA regulatory process for drugs and devices, from NDA’s to in-vitro diagnostics Class II 510(k) & Class III PMA as well as CLIA and CAP laboratory certifications.

Mr. Welch has an MBA from Harvard University and a BS in Chemical Engineering from University of California at Berkeley.


email print
3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message